

# Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease

A Livraghi-Butrico<sup>1</sup>, BR Grubb<sup>1</sup>, KJ Wilkinson<sup>1</sup>, AS Volmer<sup>1</sup>, KA Burns<sup>1</sup>, CM Evans<sup>2</sup>, WK O'Neal<sup>1,3</sup> and RC Boucher<sup>1,3</sup>

Airway diseases, including cigarette smoke-induced chronic bronchitis, cystic fibrosis, and primary ciliary dyskinesia are associated with decreased mucociliary clearance (MCC). However, it is not known whether a simple reduction in MCC or concentration-dependent mucus adhesion to airway surfaces dominates disease pathogenesis or whether decreasing the concentration of secreted mucins may be therapeutic. To address these questions, *Scnn1b*-Tg mice, which exhibit airway mucus dehydration/adhesion, were compared and crossed with *Muc5b*- and *Muc5ac*-deficient mice. Absence of *Muc5b* caused a 90% reduction in MCC, whereas *Scnn1b*-Tg mice exhibited an ~50% reduction. However, the degree of MCC reduction did not correlate with bronchitic airway pathology, which was observed only in *Scnn1b*-Tg mice. Ablation of *Muc5b* significantly reduced the extent of mucus plugging in *Scnn1b*-Tg mice. However, complete absence of *Muc5b* in *Scnn1b*-Tg mice was associated with increased airway inflammation, suggesting that *Muc5b* is required to maintain immune homeostasis. Loss of *Muc5ac* had few phenotypic consequences in *Scnn1b*-Tg mice. These data suggest that: (i) mucus hyperconcentration dominates over MCC reduction alone to produce bronchitic airway pathology; (ii) *Muc5b* is the dominant contributor to the *Scnn1b*-Tg phenotype; and (iii) therapies that limit mucin secretion may reduce plugging, but complete *Muc5b* removal from airway surfaces may be detrimental.

## INTRODUCTION

Secretion and clearance of mucus constitute a conserved mechanism for host protection across species. Airway mucus, a heterogeneous mixture of water, mucins, proteins, salts, and lipids, is traditionally listed among lung innate defenses owing to its ability to trap and mediate swift removal of inhaled particles/pathogens by mechanical clearance.<sup>1</sup> Effective mucus clearance is essential for respiratory health, as illustrated by the poor prognosis of lung diseases characterized by airway mucus stasis, e.g., cystic fibrosis, primary ciliary dyskinesia, the bronchitis associated with chronic obstructive pulmonary disease, and bronchiectasis. Regardless of etiology, all of these bronchitic diseases share the common hallmarks of abnormal sputum production and an airway pathology reflecting epithelial remodeling, mucus accumulation, and

inflammation. Increasing efforts have been focused on understanding airway mucus biology and, in particular, how the abnormal structure and function of mucus may produce disease. A complex picture is emerging, where the particular features of diseased mucus might include abnormal concentration (“hydration”),<sup>2–4</sup> biogenesis and pH,<sup>5–8</sup> macromolecular organization,<sup>9,10</sup> and/or functional relationships with other components of the host defense, including inflammatory cells.<sup>11–13</sup>

The gel-forming mucins MUC5AC and MUC5B, as well as their murine homologs *Muc5ac* and *Muc5b*, are the principal macromolecular components of airway mucus and dominate its biophysical properties.<sup>14–16</sup> Once secreted into the extracellular space, gel-forming mucins are found as mucin/protein complexes with seemingly organized structures.<sup>10</sup> MUC5AC

<sup>1</sup>University of North Carolina Marsico Lung Institute/ Cystic Fibrosis Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA and <sup>2</sup>Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA. Correspondence: A Livraghi-Butrico (alessandra\_livraghi@med.unc.edu)

<sup>3</sup>These authors contributed equally to this work.

Received 28 October 2015; accepted 18 June 2016; published online 20 July 2016. doi:10.1038/mi.2016.63

and MUC5B are different in terms of domain structure, glycosylation, assembly, and secretion sites,<sup>17</sup> and are thus predicted to have different functions. In humans, cigarette smoke-induced chronic bronchitis, cystic fibrosis, and primary ciliary dyskinesia are characterized predominately by increases in MUC5B, whereas MUC5AC may be the predominant mucin expressed in asthma.<sup>3,15,18</sup> Recent reports have identified Muc5b as essential for mucociliary clearance (MCC)<sup>19</sup> and Muc5ac hypersecretion as a major determinant of hyper-reactivity to inhaled methacholine in allergen-challenged mouse airways.<sup>20</sup> However, the functional significance of these two mucins in the pathogenesis of bronchitic lung diseases remains to be fully elucidated.

Defective mucus clearance has been experimentally generated in *Scnn1b*-transgenic (*Scnn1b*-Tg) mice by airway-targeted overexpression of the epithelial Na<sup>+</sup> channel  $\beta$  subunit ( $\beta$ ENaC, encoded by the *Scnn1b* gene).<sup>21</sup> Expression of the *Scnn1b* transgene causes airway surface dehydration with a consequent increase in mucus concentration, which leads to osmotic compression of cilia, mucus adhesion, and airway obstruction. As noted above, airway clearance is also reduced in *Muc5b* knock-out (*Muc5b*<sup>-/-</sup>) mice,<sup>19</sup> but because these two mouse models have been studied independently, the relative contributions of “low” vs. “high” mucin concentration mechanisms that degrade mucus clearance to the pathogenesis of bronchitic lung diseases are unknown.

The overall goal of the present study was to test which specific defect(s) in the mucus clearance system, i.e., mucus hyperconcentration/adhesion as observed in the *Scnn1b*-Tg model, or selective reduction in mucus flow, as observed in the *Muc5b*<sup>-/-</sup> model, produce the pathologic correlate of bronchitis, e.g., airway remodeling, inflammation, and mucus accumulation. Further, we investigated which of the major secreted mucins (Muc5ac or Muc5b) dominates the muco-obstructive phenotype of *Scnn1b*-Tg mice and whether genetic reductions in mucin concentration might be advantageous. To address these questions, we crossed *Muc5b*<sup>-/-</sup> mice or *Muc5ac*<sup>-/-</sup> mice with *Scnn1b*-Tg mice and characterized the phenotype of the progeny.

## RESULTS

### Survival and body weights of the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross progeny

The *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross generated mice of six different genotypes: *Muc5b*<sup>+/+</sup>, *Muc5b*<sup>+/-</sup>, and *Muc5b*<sup>-/-</sup> either positive (*Scnn1b*-Tg) or negative for *Scnn1b* overexpression (see Methods for the mouse nomenclature adopted in the main text and legends). *Scnn1b*-Tg mice exhibited only mild lethality compared with wild-type (WT) littermates (Supplementary Figure S1a online), regardless of their *Muc5b* genotype, as expected for mice in a mixed C57BL/6N<sup>22</sup>:129/SV<sup>23</sup> genetic background. At postnatal day (PND) 35, *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice exhibited a slight reduction in body weight as compared with *Muc5b*<sup>+/+</sup> littermates (Supplementary Figure S1b and c),

but this finding was not apparent in the progeny of congenic C57 *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg mice (Supplementary Figure S1d-f).

### Mucus hyperconcentration/adhesion is necessary to produce bronchitic lung pathology

To determine whether mucus hyperconcentration/adhesion or reduced mucus flow *per se* can produce bronchitic lung pathology, we first compared *Muc5b*<sup>-/-</sup> and *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice vs. *Muc5b*<sup>+/+</sup> littermates. Histologically, *Muc5b*<sup>-/-</sup> mice were indistinguishable from *Muc5b*<sup>+/+</sup> littermates (Figure 1a-c). In contrast, *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice exhibited a severe bronchitic pathology characterized by inflammatory infiltrates, luminal secretions, and emphysematous lesions (Figure 1a-c). Airway mucus content was evaluated histologically with Alcian Blue-Periodic Acid Schiff staining (Figure 1d) and quantified morphometrically as mucus volume density (mucus V<sub>s</sub><sup>24</sup>) in the airways (epithelial + lumen, Figure 1e) and in the epithelia alone (Figure 1f). The mucus content in *Muc5b*<sup>+/+</sup> and *Muc5b*<sup>-/-</sup> mice was minimal, and mostly confined to the intraepithelial compartment (Figure 1e). In contrast, *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice exhibited substantial intraluminal mucus accumulation, consistent with muco-obstructive lung disease. Secreted mucins were also evaluated by western blots of bronchoalveolar lavage (BAL) (Figure 1f, g and Supplementary Figure S2, upper panels). Muc5b was absent in *Muc5b*<sup>-/-</sup> mice, and the Muc5b BAL content was greatly increased in *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice, consistent with previous reports.<sup>25</sup> Parallel quantification of Muc5ac content revealed a modest increase in *Muc5b*<sup>-/-</sup> mice as compared with *Muc5b*<sup>+/+</sup> mice (~3-fold, *P* < 0.05, Figure 1h), in agreement with previous mRNA and immunohistological data.<sup>19</sup> *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice exhibited a significant increase in Muc5ac (~18-fold vs. *Muc5b*<sup>+/+</sup> mice, Figure 1h), in agreement with previous mRNA data<sup>24</sup> and suggesting accumulation of Muc5ac due to poor clearance.

### Muc5b deletion ameliorates airway mucus obstruction in *Scnn1b*-Tg mice


The effect of *Muc5b* genetic deletion on the phenotype of *Scnn1b*-Tg mice was evaluated by comparing *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg and *Muc5b*<sup>+/-</sup> *Scnn1b*-Tg mice vs. *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg littermates. Histologically, all three genotypes exhibited prominent airway inflammation (Figure 1a, b) and parenchymal remodeling (Figure 1a, c).

Notably, *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice exhibited a significant reduction in intraluminal mucus as compared with *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice, but secretions adherent to airway surfaces were still detected (Figure 1d, e). A genotype-dependent reduction in BAL Muc5b content was noted in *Muc5b*<sup>+/-</sup> *Scnn1b*-Tg and *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice (Figure 1g), reflecting allelic insufficiency and complete deletion of *Muc5b*, respectively. Also, there was a genotype-dependent increase in BAL Muc5ac content in *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice (~46-fold vs. *Muc5b*<sup>+/+</sup> mice and ~2.5-fold vs. *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice, Figure 1h), likely contributing to the residual mucus observed in the airways (Figure 1d).


### Muc5ac deletion does not ameliorate airway mucus obstruction in *Scnn1b*-Tg mice

Initial crosses between *Muc5ac*<sup>-/-</sup> and *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg mice in the C57:129 background generated mice of four

different genotypes (*Muc5ac*<sup>+/-</sup>; *Muc5ac*<sup>-/-</sup>; *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg; and *Muc5ac*<sup>-/-</sup> *Scnn1b*-Tg) in the expected Mendelian proportions, and all exhibited high survival (Supplementary Figure S3a). Analyses performed on the



**Figure 1** Mucus hyperconcentration/adhesion is necessary to produce bronchitic lung pathology, but *Muc5b* deletion ameliorates airway mucus obstruction in *Scnn1b*-Tg mice. (a) Representative photomicrographs of airway lumens cut in cross section proximal to the hilum from PND35 mice of the indicated genotypes, stained with H&E illustrating airway mucus obstruction and inflammatory infiltrates characteristic of bronchitic lung pathology in *Scnn1b*-Tg mice. (b and c) Semiquantitative histology scores for airway inflammation (b) and air space enlargement (c) in PND35 mice from the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross in the C57:129 genetic background. *n* = 6–9 mice/genotype. ANOVA \**P* < 0.05 vs. *Muc5b*<sup>+/+</sup> mice. (d) Equivalent sections as in (a) stained with AB-PAS for mucopolysaccharides, illustrating significant amelioration of mucus obstruction in *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg vs. *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice. Scale bar 0.1 mm. (e and f) Morphometric analysis of total (epithelial + luminal, e) and epithelial (f) airway mucus volume density (*V*<sub>s</sub>) in PND35 mice (C57:129 genetic background). *n* = 6–9 mice/genotype. ANOVA \**P* < 0.05 vs. *Muc5b*<sup>+/+</sup> mice, #*P* < 0.05 vs. *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice. (g and h) Densitometric analysis of mucin agarose western blots of BAL from the progeny of the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross in the C57 congenic background, at PND35. Blots were probed with anti-*Muc5b* (g) or anti-*Muc5ac* (h) antibodies. *n* = 6 mice/genotype. ANOVA \**P* < 0.05 vs. *Muc5b*<sup>+/+</sup> mice, #*P* < 0.05 vs. *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice. AB-PAS, Alcian Blue-Periodic Acid Schiff staining; ANOVA, analysis of variance; BAL, bronchoalveolar lavage; H&E, hematoxylin and eosin; PND, postnatal day.



**Figure 2** Muc5ac deletion does not ameliorate airway mucus obstruction in *Scnn1b*-Tg mice. **(a)** Representative photomicrographs of proximal left lobe main stem bronchus from PND35 mice of the indicated genotypes, stained with AB-PAS for mucopolysaccharides, illustrating no changes in mucus obstruction in *Muc5ac*<sup>-/-</sup> *Scnn1b*-Tg vs. *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg mice. Scale bar 0.1 mm. **(b and c)** Morphometric analysis of total (epithelial + luminal, **b**) and epithelial (**c**) airway mucus volume density ( $V_s$ ) in PND35 mice (C57:129 genetic background).  $n=6-11$  mice/genotype. ANOVA \* $P<0.05$  vs. *Muc5ac*<sup>+/-</sup> mice. **(d and e)** Densitometric analysis of mucin agarose western blots of BAL from the progeny of the *Muc5ac*<sup>-/-</sup>  $\times$  *Scnn1b*-Tg cross in the C57 congenic background, at PND35. Blots were probed with anti-Muc5b (**d**) or anti-Muc5ac (**e**) antibodies.  $n=6$  mice/genotype. ANOVA \* $P<0.05$  vs. *Muc5ac*<sup>+/-</sup> mice, # $P<0.05$  vs. *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg mice. AB-PAS, Alcian Blue-Periodic Acid Schiff staining; ANOVA, analysis of variance; BAL, bronchoalveolar lavage; PND, postnatal day.


progeny of congenic C57BL/6N mice bred to generate all six possible genotypes (*Muc5ac*<sup>+/-</sup>  $\times$  *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg) confirmed that *Muc5ac* deletion did not significantly affect survival (**Supplementary Figure S3b**) or body mass (**Supplementary Figure S3c and d**).

Similar to the cross with *Muc5b*<sup>-/-</sup> mice, only *Scnn1b*-Tg mice exhibited bronchitic lung pathology when evaluated on hematoxylin and eosin-stained sections, regardless of *Muc5ac* genotype (not shown). However, in contrast to what was observed for the *Muc5b*<sup>-/-</sup> cross, there were no differences in Alcian Blue-Periodic Acid Schiff staining-positive mucus content, either luminal or epithelial, between *Muc5ac*-deficient or -sufficient *Scnn1b*-Tg mice (**Figure 2a-c**). These data suggest that *Muc5ac* did not significantly contribute to the intraluminal mucus plugging observed in *Scnn1b*-Tg mice. Quantitation of BAL mucin content (**Figure 2d, e** and **Supplementary Figure S2**, lower panels) revealed that, contrary to *Muc5b*<sup>-/-</sup> mice, *Muc5ac*<sup>-/-</sup> mice did not exhibit a compensatory increase in *Muc5b* compared with *Muc5ac*<sup>+/-</sup> mice. *Muc5b* signal was increased in *Scnn1b*-Tg mice, regardless of *Muc5ac* genotype. As for *Muc5ac* BAL content, the signal

for *Muc5ac*<sup>+/-</sup> and *Muc5ac*<sup>-/-</sup> mice was just above background, but an increased level of *Muc5ac* was observed in *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg mice. Of note, there was a genotype-dependent reduction of harvested *Muc5ac* in *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg and *Muc5ac*<sup>-/-</sup> *Scnn1b*-Tg mice, reflecting the *Muc5ac* allelic make-up of the mice.

#### Relative contribution of *Muc5ac* vs. *Muc5b* to neonatal survival in a model of lethal mucus obstruction, the F1 C57:FVB *Scnn1b*-Tg mouse


As previously reported, the severity of the *Scnn1b*-Tg mucobstructive phenotype is proportional to airway mucin secretory capacity, which is age- and mouse strain-dependent.<sup>22</sup> Specifically, we and others have reported that neonatal mice experience a transient increase in *Muc5ac* and *Muc5b* secretion during the early postnatal period (PND5-10).<sup>25,26</sup> The developmentally regulated increase in mucin concentration on airway surfaces, coupled to the small caliber of neonatal airways, makes *Scnn1b*-Tg pups more sensitive to the impact of salt and water depletion produced by *Scnn1b*-Tg overexpression and causes fatal tracheal mucus obstruction. We have



**Figure 3** Relative contribution of Muc5ac vs. Muc5b to neonatal survival in a model of lethal mucus obstruction, the F1 C57:FVB/NJ *Scnn1b*-Tg mice. Survival curves for the progeny of the *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice (a) or *Muc5ac*<sup>-/-</sup> *Scnn1b*-Tg mice (b) crossed with inbred FVB/NJ mice. Muc5b heterozygosity improved overall survival of F1 C57:FVB *Scnn1b*-Tg mice, whereas Muc5ac heterozygosity only resulted in delayed time of death (median survival PND9 vs. PND5 for *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg mice vs. *Muc5ac*<sup>+/+</sup> *Scnn1b*-Tg mice, respectively). \**P*<0.05 vs. *Muc*<sup>+/+</sup> littermates, #*P*<0.05 vs. *Muc*<sup>+/+</sup> *Scnn1b*-Tg littermates. PND, postnatal day.

previously described a variant of *Scnn1b*-Tg mice, F1 C57:FVB *Scnn1b*-Tg mice,<sup>22</sup> characterized by extremely high postnatal mortality (90%) and higher BAL mucus content as compared with congenic C57BL/6N *Scnn1b*-Tg mice.

Accordingly, we crossed *Muc5ac*<sup>-/-</sup> *Scnn1b*-Tg mice or *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice with inbred FVB/NJ mice to obtain mice of four different genotypes (*Muc*<sup>+/+</sup>, *Muc*<sup>+/-</sup>, *Muc*<sup>+/+</sup> *Scnn1b*-Tg, *Muc*<sup>+/-</sup> *Scnn1b*-Tg) in a homogeneous F1 C57:FVB genetic background. The effect of decreased Muc5ac or Muc5b concentration on survival was evaluated. *Muc5b*<sup>+/+</sup> and *Muc5b*<sup>+/-</sup> mice had the expected normal, high survival, whereas *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice were all dead within 7 days from birth (Figure 3a). Importantly, heterozygosity for *Muc5b* significantly improved the survival of *Muc5b*<sup>+/-</sup> *Scnn1b*-Tg mice (~70% at PND10) as compared with *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice (~0% at PND10). When similar studies were performed with *Muc5ac*<sup>-/-</sup> mice, we observed no protection from lethality (Figure 3b) but a modest though significant delay in mortality of the *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg mice as compared with *Muc5ac*<sup>+/+</sup> *Scnn1b*-Tg mice. Collectively, these data suggest that Muc5b is the dominant mucin that leads to lethality of *Scnn1b*-Tg mice in the “high mucus producer” FVB background.



**Figure 4** Mucociliary transport only partially correlates with the severity of muco-obstructive lung disease. Mucociliary clearance measurements in selected genotypes from the progeny of the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross in the C57 congenic background, at PND35. *n* = 6–14 mice/genotype. ANOVA \**P*<0.05 vs. *Muc5b*<sup>+/+</sup> mice, #*P*<0.05 vs. *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice. ANOVA, analysis of variance; PND, postnatal day.

#### Mucociliary transport only partially correlates with the severity of muco-obstructive lung disease


A key measurement that has been used to relate airway mucus function to disease has been the rate of MCC.<sup>2</sup> Accordingly, we compared the relative rates of mucus transport in the two models of defective airway clearance, i.e., *Scnn1b*-Tg and *Muc5b*<sup>-/-</sup> mice. Furthermore, to test whether a reduction in mucin concentration in the lungs of *Scnn1b*-Tg mice produced by absence of Muc5b might rescue mucus transport, we also measured MCC in *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg.

As shown in Figure 4, *Muc5b*<sup>+/+</sup> mouse lungs cleared ~75% of the tracer particles within 15 min after instillation. In contrast, there was almost a complete loss of MCC in *Muc5b*<sup>-/-</sup> mice, as previously reported.<sup>19</sup> Also, similar to previous reports,<sup>21</sup> a ~50% reduction in MCC was observed in *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice. Notably, deletion of Muc5b in *Scnn1b*-Tg mice did not rescue mucus transport, but rather caused a reduction in MCC towards the levels exhibited by *Muc5b*<sup>-/-</sup> mice.

#### Deletion of Muc5b or Muc5ac does not affect bacterial burden or ameliorate airway inflammation in *Scnn1b*-Tg mice

Because both *Scnn1b*-Tg and *Muc5b*<sup>-/-</sup> mice have increased susceptibility to spontaneous and experimentally induced airway bacterial infection,<sup>19,21,27</sup> we tested whether the combination of the two genotypes would produce an additive phenotype. As effects of Muc5ac deletion on intestinal pathogen clearance have also been reported,<sup>28</sup> microbiology experiments were also performed for the *Muc5ac*<sup>-/-</sup> × *Scnn1b*-Tg cross.

At PND5–7, *Muc5b*<sup>-/-</sup> mice exhibited an incidence of infection of ~50% compared with 0% in *Muc5b*<sup>+/+</sup> mice, with a bacterial burden of ~1.5 Log CFU per mouse (Figure 5a). In contrast, virtually all neonatal *Scnn1b*-Tg



**Figure 5** Deletion of *Muc5b* does not affect bacterial burden or ameliorate airway inflammation in *Scnn1b*-Tg mice. **(a and b)** Quantification of CFU in BAL samples from the progeny of the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross in the C57:129 genetic background, at PND5–7 **(a)** or PND35 **(b)**. (Log<sub>10</sub> + 1)-transformed data. *n* = 8–24 mice/genotype **(a)** and *n* = 5–8 mice/genotype **(b)**. ANOVA \**P* < 0.05 vs. *Muc5b*<sup>+/+</sup> mice. **(c and d)** BAL neutrophil counts for the progeny of the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross in the C57:129 genetic background, at PND5–7 **(c)** or PND35 **(d)** *n* = 7–24 mice/genotype **(c)** and *n* = 11–15 mice/genotype **(d)**. ANOVA \**P* < 0.05 vs. *Muc5b*<sup>+/+</sup> mice. ANOVA, analysis of variance; BAL, bronchoalveolar lavage; CFU, colony-forming units; PND, postnatal day.


mice were infected with a bacterial burden of ~3 Log CFU per mouse, and this infection was not affected by the *Muc5b* genotype. At PND35, none of the *Muc5b*<sup>-/-</sup> mice were infected, and sporadic infections were detected in *Scnn1b*-Tg mice (**Figure 5b**), in agreement with previous reports.<sup>27</sup> Similar to neonatal *Scnn1b*-Tg mice, there was no appreciable difference in bacterial burden due to *Muc5b* genotype in adult WT or *Scnn1b*-Tg mice. A similar picture emerged from the microbiological analysis of BAL samples harvested from mice derived from *Muc5ac*<sup>-/-</sup> × *Scnn1b*-Tg crosses at PND5–7 (**Supplementary Figure S4**), with the notable exception that *Muc5ac*<sup>-/-</sup> neonatal mice did not exhibit the incidence of spontaneous bacterial infection observed in neonatal *Muc5b*<sup>-/-</sup> mice.

To test whether genetic ablation of *Muc5ac* or *Muc5b* affected the airway inflammatory profile of *Scnn1b*-Tg mice, we characterized BAL cells in neonatal (PND5–7) and adult (PND35) mice. Neutrophil counts were elevated in both *Muc5b*<sup>-/-</sup> and *Muc5b*<sup>+/-</sup> × *Scnn1b*-Tg neonatal mice as compared with *Muc5b*<sup>+/+</sup> littermates (**Figure 5c**), in agreement with the presence of bacteria. Rather than rescuing this phenotype, *Muc5b* deletion caused a trend towards worsening of the neutrophil infiltration in *Scnn1b*-Tg mice. In adult mice, there was a modest but significant increase in neutrophil count in *Muc5b*<sup>-/-</sup> mice, whereas the neutrophil infiltrate was much greater in *Muc5b*<sup>+/+</sup> × *Scnn1b*-Tg mice (**Figure 5d**). However, the airway neutrophilia typical of adult *Scnn1b*-Tg mice was not ameliorated by either partial (*Muc5b*<sup>+/-</sup> × *Scnn1b*-Tg mice) or total (*Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg

mice) ablation of *Muc5b*. Rather, a gene-dosage-dependent trend towards worsening of airway neutrophilia was observed (*Muc5b*<sup>+/+</sup> > *Muc5b*<sup>+/-</sup> > *Muc5b*<sup>-/-</sup>). *Muc5b* deletion alone was not associated with significant changes in macrophage numbers either in neonatal (**Supplementary Figure S5a**) or adult WT mice (**Supplementary Figure S5b**). Neonatal *Scnn1b*-Tg mice exhibited a modest increase in BAL macrophages as compared with WT littermates, regardless of *Muc5b* genotype, but this increase was normalized in adult mice with only *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg mice exhibiting a significant difference vs. WT littermates.

As a parallel readout of airway inflammation, we evaluated the BAL chemokine and cytokine profiles in adult mice. The neutrophil chemoattractant chemokines (C-X-C motif) ligand 1 (CXCL1 or KC) and lipopolysaccharide-induced CXC chemokine (LIX) were significantly elevated in *Scnn1b*-Tg mice as compared with both WT and *Muc5b*<sup>-/-</sup> mice (**Figure 6a,b**). Genetic deletion of *Muc5b* did not alter the levels of these inflammatory markers in *Scnn1b*-Tg mice. Although it did not reach significance, macrophage inflammatory protein (MIP)-2 was elevated in all *Scnn1b*-Tg samples, regardless of *Muc5b* genotype (**Supplementary Figure S5c**), whereas IL-6 and TNFα were below the lower limit of detection in all samples (data not shown).

As for the progeny of the *Muc5ac*<sup>-/-</sup> × *Scnn1b*-Tg cross, partial or total *Muc5ac* deletion did not cause neutrophilia or altered BAL macrophage counts in either neonatal (**Supplementary Figure S6a and c**) or adult (**Supplementary Figure S6b and d**) WT mice. Of note,



**Figure 6** Deletion of *Muc5b* does not alter the BAL chemokine and cytokine profile in *Scnn1b*-Tg mice. KC (**a**) and LIX (**b**) levels in cell-free BAL from the progeny of the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross in the C57:129 genetic background at PND35. The dotted line represents the assay LOD. *n* = 5–8 mice/genotype. ANOVA \**P* < 0.05 vs. *Muc5b*<sup>+/+</sup> mice. ANOVA, analysis of variance; BAL, bronchoalveolar lavage; LOD, lower detection limit.

*Muc5ac* deletion did not rescue the BAL neutrophilia in either neonatal or adult *Scnn1b*-Tg mice (**Supplementary Figure S6a and b**), and only a slight increase in BAL macrophage numbers was detected in neonatal *Muc5ac*<sup>-/-</sup> *Scnn1b*-Tg mice as compared with WT littermates (**Supplementary Figure S6d**).

#### Deletion of *Muc5b*, but not *Muc5ac*, worsens the incidence of bronchus-associated lymphoid tissue (BALT) in *Scnn1b*-Tg mice

Histopathological analysis of lung sections stained with hematoxylin and eosin (**Figure 7a**) using a semiquantitative score<sup>25</sup> (**Supplementary Figure S7a and b**) and quantitative morphometry (**Figure 7b**) indicated that BALT was absent in PND35 WT mice, regardless of *Muc5ac* or *Muc5b* genotype, whereas low level accumulation of this ectopic lymphoid tissue could be detected in mucin-sufficient *Scnn1b*-Tg mice at this time point. Of note, *Muc5b* deletion significantly increased the incidence of BALT in *Scnn1b*-Tg mice, whereas *Muc5ac* deletion did not modify this phenotype. This increase in BALT was not reflected in the total number of BAL lymphocytes, which was elevated in *Scnn1b*-Tg mice regardless of *Muc5b* genotype (**Figure 7c**). Both B and T cells were present in these lymphoid nodules (**Figure 7d**), and their rather loose organization suggested recently formed, inducible BALT.<sup>29</sup>


We sought to determine whether there was a correlation between incidence of BALT and immunoglobulin

concentrations in BAL harvested from the progeny of the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross. A striking increase in IgA was observed in all *Scnn1b*-Tg samples, regardless of *Muc5b* genotype (**Figure 8a**). Except for an increase in IgG<sub>1</sub> in *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice (**Figure 8b**), no systematic differences were observed for other IgG subtypes or IgM as a function of *Muc5b* genotype (**Supplementary Figure S8a–d**). Longitudinal studies comparing *Scnn1b*-Tg and WT littermates showed that IgA levels are increased in the BAL of *Scnn1b*-Tg mice beginning at PND10 (**Supplementary Figure S8e**). As it has been proposed that IgA binding to mucus through the polymeric Ig receptor secretory component (SC) is essential for IgA function in the lung,<sup>30</sup> we tested whether selective deletion of *Muc5b* or *Muc5ac* would modify the localization of SC in WT or *Scnn1b*-Tg mice. As shown in **Figure 8c**, SC was exclusively localized to the surface epithelium in both *Muc5b*<sup>+/+</sup> and *Muc5b*<sup>-/-</sup> mice (as well as *Muc5ac*<sup>-/-</sup> mice, not shown), whereas it was abundant in the luminal mucous secretions of *Scnn1b*-Tg mice, and its localization was not altered in the absence of either *Muc5ac* or *Muc5b*.

#### DISCUSSION

Many aspects of lung mucus biology have become better defined in recent years. For example, it appears that *Muc5b*, not *Muc5ac*, is the dominant mucin that confers to the mucus layer the properties required for transport in the healthy lung.<sup>19</sup> Moreover, the dominant role of mucins in producing the biophysical properties governing mucus flow in health vs. reduced/no flow in disease has also become better appreciated. Notably, a novel paradigm posits that healthy airway surfaces are populated by two mucus hydrogel layers, one comprised of the mobile layer (where *Muc5b* is dominant) and the other comprised of the periciliary layer, enriched in tethered mucins including *Muc1*, *Muc4*, and *Muc16*.<sup>4</sup> The identification of this two-gel topology for the airway surface<sup>9</sup> is key to quantify biophysical variables related to the distribution of water between the two hydrogels, which ultimately determines the efficiency of mucus transport.<sup>4</sup> Of particular relevance for this study is the notion that mucus clearance is inversely proportional to its concentration, a concept recently translated to the clinic.<sup>2</sup>

It is clear that mucins have an important role in the pathogenesis of bronchitic lung diseases, which are clinically characterized by increased sputum production over defined periods of time, and pathologically associated with airway epithelial remodeling, including goblet cell metaplasia, inflammation, and mucus plugging. Despite the likely importance of mucus in the pathogenesis of these diseases, it is not clear whether abnormal qualitative or quantitative properties of mucus produce disease. Specifically, it is not clear whether the simple absence of mucus clearance, abnormal ratios of MUC5AC to MUC5B, or abnormal mucus concentration are required features to initiate pathology. Heretofore, it has been difficult to experimentally separate the two different pathologic mechanisms, e.g., absence of transport vs. presence of hyperconcentration, which is key to address this question.



**Figure 7** Deletion of *Muc5b*, but not *Muc5ac*, worsens the incidence of BALT in *Scnn1b-Tg* mice. (a) Representative micrographs of proximal left lobe main stem bronchus from PND35 mice, stained with H&E, illustrating typical histopathology for the indicated genotypes. Scale bar 0.2 mm. Airway mucus obstruction was evident in *Muc5b*<sup>+/+</sup> *Scnn1b-Tg* mice and *Muc5ac*<sup>-/-</sup> *Scnn1b-Tg* mice (asterisks), but it was less severe in *Muc5b*<sup>-/-</sup> *Scnn1b-Tg* mice. However, *Muc5b*<sup>-/-</sup> *Scnn1b-Tg* mice presented with a higher incidence of BALT (arrow and high magnification inset, scale bar 20  $\mu$ m).

(b) Morphometric analysis of BALT in PND35 mice (C57:129 genetic background).  $n = 6-9$  mice/genotype. ANOVA  $*P < 0.05$  vs. *Muc5b*<sup>+/+</sup> mice.


(c) BAL lymphocyte counts for the progeny of the *Muc5b*<sup>-/-</sup>  $\times$  *Scnn1b-Tg* cross in the C57:129 genetic background, at PND35.  $n = 11-15$  mice/genotype. ANOVA  $*P < 0.05$  vs. *Muc5b*<sup>+/+</sup> mice.

(d) Representative confocal images of BALT immunostained with B and T cells specific markers (B220 in red and CD3 in green, respectively), and relevant isotype negative controls (rat IgG2a,k and goat IgG, respectively). Nuclei are stained in blue (DAPI). DIC image is provided to illustrate the typical localization of BALT in the airway submucosal compartment. ANOVA, analysis of variance; BAL, bronchoalveolar lavage; BALT, bronchus-associated lymphoid tissue; DIC, differential interference contrast; H&E, hematoxylin and eosin; PND, postnatal day.

Recently, the opportunity to study the role of mucins subtypes, mucus concentration, and mucus transport in the pathogenesis of bronchitic lung disease has been afforded by the generation of mouse models that produced different

perturbations of airway mucus biology. Specifically, the availability of *Muc5b*<sup>-/-</sup> mice, which exhibit very slow airway mucus transport,<sup>19</sup> and *Scnn1b-Tg* mice, which exhibit airway mucus hyperconcentration and adhesion to airway





**Figure 8** Airway mucus hyperconcentration/adhesion stimulates IgA secretion. (a and b) IgA (a) and IgG<sub>1</sub> (b) levels in cell-free BAL from the progeny of the *Muc5b*<sup>-/-</sup> × *Scnn1b*-Tg cross in the C57:129 genetic background at PND35. The dotted line represents the assay LOD. *n* = 5–8 mice/genotype. ANOVA \**P* < 0.05 vs. *Muc5b*<sup>+/+</sup> mice. (c) Immunohistochemical localization of the polymeric Ig receptor SC in the main stem bronchus of mice for the indicated genotypes. A serial section to the one used for *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg SC stain is shown as negative IgG control (IgG control). ANOVA, analysis of variance; BAL, bronchoalveolar lavage; LOD, lower detection limit; SC, secretory component.

surfaces,<sup>21</sup> has provided the opportunity to assess the relative roles and possible interactions of these dysfunctions in a common cohort.

In the studies reported here, the progenies from the mucin-deficient × *Scnn1b*-Tg mice crosses were compared utilizing metrics of bronchitic disease severity. Mucin-sufficient *Scnn1b*-Tg mice exhibited a relatively severe bronchitic phenotype, including: (i) increased airway mucus burden (Figures 1 and 2); (ii) highly penetrant spontaneous bacterial infection (Figure 5); (iii) significant inflammatory infiltrates (Figure 5); (iv) epithelial/parenchymal remodeling (Figures 1 and 7); and (v) increase in pro-inflammatory cytokines (Figure 6) consistent with previous reports.<sup>24,25,27</sup> Novel to this study, we observed another index of increased immune responses, i.e., high concentrations of IgA in *Scnn1b*-Tg BALF (Figure 7e). In contrast, *Muc5b*<sup>-/-</sup> mice exhibited a milder disease, with a lesser incidence of bacterial infection, fewer BAL neutrophils, lower levels of pro-inflammatory cytokines and IgA, and importantly no histological evidence of airway epithelial remodeling or emphysema. In parallel, no evidence of

spontaneous lung disease was observed in *Muc5ac*<sup>-/-</sup> mice, consistent with previous reports.<sup>20</sup>

Interestingly, the severity of the obstructive and inflammatory airway phenotype did not simply reflect the rates of airway mucus clearance. As shown in Figure 4, airway MCC in *Muc5b*<sup>-/-</sup> mice was indeed lower than in *Scnn1b*-Tg mice, despite the milder phenotype of the former. Accordingly, we speculate that it is not a reduction in the absolute rate of mucus clearance that dominates the pathogenesis of bronchitis, but it is the presence of hyperconcentrated mucus adherent to the airway surfaces, as evident in *Scnn1b*-Tg mice (Figures 1, 2, and 7). This interpretation is consistent with findings in other mouse models that exhibit defective mucus transport but lack a mucus-adhesive component, e.g., models of primary ciliary dyskinesia, which also exhibit a mild lower airway phenotype.<sup>31–33</sup>

Crossing the *Muc5b*<sup>-/-</sup> and *Muc5ac*<sup>-/-</sup> mice with *Scnn1b*-Tg mice also offered the opportunity to query the role of the two major secreted mucins in the development of the *Scnn1b*-Tg phenotype. *Muc5ac*-deficient *Scnn1b*-Tg mice exhibited little/no change as compared with *Muc5ac*-sufficient

*Scnn1b*-Tg mice (Figure 2). In contrast, the magnitude of mucus obstruction in *Scnn1b*-Tg mice was significantly reduced in the absence of *Muc5b*, as evaluated both morphometrically and by BAL western blot (Figure 1e–h), consistent with the notion that *Muc5b* is the major secreted mucin in mouse airways.<sup>19,26,34</sup> Despite the reduction in mucus burden, areas of mucus adhesion persisted histologically (Figure 1d, e). These plugs likely contained *Muc5ac*, consistent with the significant accumulation of *Muc5ac* in the BAL fluid of *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice (Figure 1h).

The availability of a mouse strain that exhibits a lethal muco-obstructive phenotype, i.e., F1 C57:FVB *Scnn1b*-Tg mice, allowed us to investigate whether decreased levels of *Muc5b* or *Muc5ac* could rescue survival. Heterozygosity for *Muc5b*, but not *Muc5ac*, was sufficient to significantly rescue the survival of F1 C57:FVB *Scnn1b*-Tg mice (Figure 3). On the basis of the data that *Muc5b*<sup>+/-</sup> *Scnn1b*-Tg mice exhibit ~50% the levels of BAL *Muc5b* as compared with *Muc5b*<sup>+/+</sup> *Scnn1b*-Tg mice (Figure 1g), it is likely that the reduction of *Muc5b* was responsible for the large increase in survival. In contrast, *Muc5ac*<sup>+/-</sup> *Scnn1b*-Tg mice exhibited a modest increase in time to death as compared with *Muc5ac*<sup>+/+</sup> *Scnn1b*-Tg mice, suggesting that a Th2- or developmentally driven increase in *Muc5ac* might be detrimental to survival early in life.

Importantly, inflammation in *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice was not reduced proportionately to mucus obstruction. Instead, there was an overall increase in the severity of pulmonary inflammation as indexed by increased number of BAL neutrophils and BALT (Figures 5 and 7). These findings suggest that other factors in addition to mucus obstruction can lead to pulmonary inflammation. Perhaps the simplest explanation for the increased inflammatory phenotype in *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice is that reduction of secreted *Muc5b* did not rescue the defective airway clearance of *Scnn1b*-Tg mice but, rather, further reduced mucus clearance to the levels of *Muc5b*<sup>-/-</sup> mice (Figure 4). This reduction could promote further adhesion of other mucus components, possibly *Muc5ac*, to airway surfaces as well as prolong the residence time of pro-inflammatory particles or debris initiating a predictable inflammatory response. Alternatively, it has been reported that mucins may “communicate” with inflammatory cells, including macrophages and dendritic cells,<sup>12,13,35–37</sup> and perhaps the absence of *Muc5b* contributed *per se* to an exaggerated inflammatory response in *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice. Finally, gel-forming mucins, and particularly *Muc5b*, are associated with a network of proteins forming macromolecular complexes, known as “mucin interactomes,” which are thought to be involved in maintaining airway immune homeostasis through their anti-microbial/anti-inflammatory/anti-oxidant functions.<sup>38,39</sup> Derangement of this network may have adverse effects in controlling airway inflammation.

Another unexpected finding of this study was that *Muc5b* deletion did not affect bacterial burden in *Scnn1b*-Tg mice (Figure 5a, b) despite a reduction in mucus plugs. A possible interpretation is that while *Muc5b* deletion decreased mucus plugging, it also reduced clearance of inhaled bacteria

(as indicated by the presence of bacteria in 50% of the neonatal *Muc5b*<sup>-/-</sup> mice), offsetting the beneficial effect of reduced plugging. We can also speculate that the composition of neonatal mucus, enriched in *Muc5ac* as compared with adult mice<sup>(26 and A. Livraghi-Butrico, unpublished data)</sup>, might also contribute to increased, *Muc5b*-independent trapping of bacteria.

As noted above, we found that IgA BAL levels were elevated in *Scnn1b*-Tg mice, suggesting that mucus hyperconcentration/adhesion stimulates local IgA production and secretion. IgA levels were elevated independently of *Muc5b* genotype, suggesting that the residual degree of mucus obstruction was sufficient to stimulate IgA synthesis and secretion. Importantly, previous reports have shown that SC-mediated binding of IgA to mucus is required for its function.<sup>30</sup> Our immunohistological data (Figure 8c) suggest that SC binding to the mucus is not *Muc5ac*- or *Muc5b*-dependent. However, we cannot rule out the possibility that the overall decrease in intraluminal *Muc5b* in *Muc5b*<sup>-/-</sup> *Scnn1b*-Tg mice removed an essential “scaffold” for secreted IgA, impairing immune exclusion<sup>40</sup> and promoting inflammation.

In conclusion, mucus biology in the normal and diseased lung is complex and likely involves not only the biophysical contributions of mucins to mucus transport but also interactions with host immune cells and defense proteins. Our data suggest that mucus hyperconcentration/adhesion rather than the loss of mucus flow dominates the pathophysiology of bronchitic lung diseases, and, consequently, these diseases may be characterized as “muco-obstructive” lung diseases. So, what is pathogenic in static/adherent mucus? Mucus adhesion certainly blocks airflow, and it is in part responsible for the reduced airflow observed in muco-obstructive lung diseases. Adherent mucus is also the site of most bacterial airway infections, including those causing exacerbations in cystic fibrosis and chronic obstructive pulmonary disease, and, even when “sterile,” it appears to be a pro-inflammatory DAMP.<sup>27</sup> Moreover, mucus plugging induces local, epithelia hypoxia,<sup>24</sup> which is an increasingly recognized feature of the CB syndrome,<sup>41</sup> important for both inflammatory responses and anaerobic infection. Notably, therapies designed to clear mucus from airway surfaces are predicted to be therapeutic for these conditions. The simplest therapies involve the “rehydration” of mucus so that its concentration is restored to levels compatible with transport. It is also likely that therapies designed to reduce mucin secretion, and thus reduce concentrations, may also be useful. However, our data suggest that a complete loss of secreted mucins, especially MUC5B, may worsen pathology, so a more moderate titration might be needed therapeutically.

## METHODS

**Animals.** Animals were maintained and studied under protocols approved by the University of North Carolina Institutional Animal Care and Use Committee, according to the principles outlined by the Animal Welfare and the National Institutes of Health guidelines. Mice were housed in individually ventilated micro-isolator cages in a

specific pathogen-free facility at the University of North Carolina at Chapel Hill, on a 12-h day/night cycle. Mice were fed a regular chow diet and given water *ad libitum*.

$Muc5ac^{-/-}$ <sup>20</sup> and  $Muc5b^{-/-}$ <sup>19</sup> mice were obtained from the Laboratory of Dr Christopher Evans as C57BL/6J:129/Sv line. Congenic C57BL/6N *Scnn1b*-Tg mice and WT littermates were maintained as a hemizygous as described<sup>22</sup> and referred to as WT (i.e., *Scnn1b*-Tg<sup>-</sup> or *Scnn1b*-Tg negative) or *Scnn1b*-Tg (i.e., *Scnn1b*-Tg<sup>+</sup> or *Scnn1b*-Tg positive). Mucin-deficient *Scnn1b*-Tg mice and appropriate littermate controls were generated by sequential breeding of congenic C57BL/6N hemizygous *Scnn1b*-Tg mice with  $Muc5ac^{-/-}$  or  $Muc5b^{-/-}$  mice, using a breeding strategy previously described.<sup>25</sup> For clarity, genotypes of the progenies are indicated in the main text and figure legends as follows:  $Muc5ac^{+/+}/Scnn1b-Tg^{-} = Muc5ac^{+/+}$ ;  $Muc5ac^{+/-}/Scnn1b-Tg^{-} = Muc5ac^{+/-}$ ;  $Muc5a^{-/-}/Scnn1b-Tg^{-} = Muc5a^{-/-}$ ;  $Muc5ac^{+/+}/Scnn1b-Tg^{+} = Muc5ac^{+/+} Scnn1b-Tg$ ;  $Muc5ac^{+/-}/Scnn1b-Tg^{+} = Muc5ac^{+/-} Scnn1b-Tg$ ;  $Muc5a^{-/-}/Scnn1b-Tg^{+} = Muc5a^{-/-} Scnn1b-Tg$ ; and similarly for the  $Muc5b^{-/-} \times Scnn1b$ -Tg cross. Congenic C57BL/6N  $Muc5ac^{-/-}$  and  $Muc5b^{-/-}$  mice were generated by crossing heterozygous mice to inbred C57BL/6N mice (Taconic, Hudson, NY) for more than 12 generations. Mixed-strain or congenic mice were used as described in the text. At PND1 or 2, pups were toe clipped for identification and genotyping, as previously described.<sup>21</sup> Mice studied were littermates, age-matched, and of both sexes. Congenic FVB/NJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME).

**Bronchoalveolar lavage (BAL), cell counts, analyses of soluble contents, and bacteriology.** BAL was performed in neonatal and adult mice as previously described.<sup>25</sup> For microbiology studies, BAL was performed aseptically and colony-forming units (CFUs) were enumerated in serially plated dilutions (plated onto Columbia anaerobe sheep blood agar (Becton Dickinson, NJ) and incubated in a candle jar to facilitate the growth of microaerophilic bacteria at 37 °C for 24 h), as previously described.<sup>27</sup> Mouse TNF $\alpha$ , KC, MIP-2, LIX, IL-6, IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, IgG<sub>3</sub>, IgA, and IgM were measured in cell-free BAL using a Luminex-based assay (EMD Millipore, Billerica, MA), according to the manufacturer's instructions.

**Lung histology.** Lungs were immersion-fixed in 10% neutral-buffered formalin to prevent dislodging of airway luminal contents. Paraffin-embedded sections were stained with hematoxylin and eosin and Alcian Blue-Periodic Acid Schiff staining, and lung pathology graded as previously described using a semiquantitative histology score<sup>25</sup> or morphometry.<sup>24</sup> Tissue blocks received a numerical code at time of embedding and scoring was performed by an investigator blinded to specimen genotype.

**Agarose gel mucin western blot.** Secreted mucin quantification was carried out using a slight modification of the protocol described in Livraghi *et al.*<sup>25</sup> BAL samples were solubilized by addition of urea to reach a 6 M concentration. Samples were reduced with 10 mM dithiothreitol for 90 min at 37 °C and alkylated with 25 mM iodoacetamide for 30 min at room temperature (RT) in the dark. Equal volumes of reduced samples (40  $\mu$ l) were run on 1% agarose gel at 80 V for 90 min. Gels were vacuum-blotted onto nitrocellulose membranes with 4  $\times$  sodium citrate buffer for 2 h, blocked with Odyssey blocking buffer (OBB, Li-COR Biosciences, Lincoln, NE), and probed with rabbit polyclonal antibodies against *Muc5b* (UNC223, 1:2000 in OBB<sup>34</sup>) or *Muc5ac* (UNC294, 1:1000 in OBB + 0.1% Tween-20,<sup>42</sup>). The secondary antibody was IRDye 680LT donkey anti-rabbit IgG (Li-COR Biosciences), diluted 1:15,000 in OBB. Detection and densitometry were performed using the Odyssey Infrared Imaging System (LI-COR Biosciences).

**Mucociliary clearance (MCC) assay.** PND35 mice were anesthetized with 2–3% isoflurane and a small incision was made through the tracheal ventral wall. Using a fine-bore cannula, 200 nl of phosphate-buffered saline (PBS) containing a known number of fluorescent microspheres (3  $\mu$ m Molecular Probes FluoSpheres, Nile Red, Invitrogen,

Thermo Fisher Scientific, Rochester, NY) was deposited near the tracheal bifurcation. After the cannula was removed and the tracheostomy closed, the anesthetized mouse was allowed to breath spontaneously for 15 min. After this period, the mouse was killed, the lungs and trachea (up to the larynx) were removed and solubilized in KOH, and the beads left in the tissue were counted. MCC was determined as % of delivered beads that were cleared.

**Immunofluorescence analysis of BAL.** Lungs were inflated with a 1:1 mixture of OCT:PBS, embedded in 100% OCT and sectioned. Slides were air dried, fixed in ice cold 100% acetone for 5 min, and washed in PBS. Blocking was performed in 5% normal goat serum (Jackson ImmunoResearch Laboratories, West Grove, PA), 1:50 Fc Block (BD Biosciences, San Jose, CA, rat anti-mouse CD16/CD22 clone 2.4G2), 0.1% Tween-20, and 0.1% Triton-X in PBS, for 30 min at RT. Primary antibodies and isotype controls (goat anti-mouse CD3- $\epsilon$  (M-20) Santa Cruz Biotechnology (Dallas, TX) and goat IgG Jackson ImmunoResearch 0.2 mg ml<sup>-1</sup>, dil. 1:100; rat anti-mouse CD45R/B220 and rat IgG2a,  $\kappa$  both from BD Biosciences, dil. 1:50) were diluted in PBS + 0.1% Tween-20 + 0.1% Triton-X (PBS-TT) and incubated over night at 4 °C. Sections were washed in PBS + 0.1% Tween-20 (PBST) and secondary antibodies (donkey anti-goat AlexaFluor 633 and donkey anti-rat AlexaFluor 594, Jackson ImmunoResearch, both at 1:200 dilution in PBSTT) were applied for 60 min at RT in the dark. After washing in PBST, slides were mounted with Vectashield Soft Mount media (Vector Laboratories, Burlingame, CA) containing DAPI for nuclear staining, and imaged by confocal microscopy, using a Leica SP2 microscope with an Apochromat  $\times$ 40/1.25 NA oil immersion lens (Leica Microsystems, Buffalo Grove, IL).

**Immunohistochemical localization of SC.** Lungs were immersion fixed in 10% neutral-buffered formalin for 24 h. Paraffin-embedded sections were incubated at 65 °C for 2–4 h, and deparaffinized with xylene (2 changes  $\times$  5') and graded ethanol (100%  $2 \times 5'$ , 95%  $1 \times 5'$ , 70%  $1 \times 5'$ ). After rehydration, antigen retrieval was performed by boiling the slides in 0.1 M sodium citrate pH 6.00 (3 cycles with microwave settings: 100% power for 6.5 min, 60% for 6 min, and 60% for 6 min, refilling the Coplin jars with deionized water after each cycle). After cooling and rinsing with dH<sub>2</sub>O, quenching of endogenous peroxidase was performed with 0.5% H<sub>2</sub>O<sub>2</sub> in methanol for 15 min, slides were washed in PBS, and blocked with 5% normal donkey serum, 1:50 Fc block in PBS-T, for 1 h at RT. Primary antibodies and isotype control (goat anti-mouse pIgR R&D Systems (Minneapolis, MN) AF2800 and goat IgG Jackson ImmunoResearch 0.2 mg ml<sup>-1</sup>) were diluted in 5% normal donkey serum in PBST and incubated over night at 4 °C. Sections were washed in PBS and secondary antibody (biotinylated donkey anti-goat IgG, Jackson ImmunoResearch, at 1:200 dilution in 5% normal donkey serum in PBST) was applied for 30 min at RT. After washing in PBST, slides were incubated with avidin-peroxidase complex according to the manufacturer instruction (Vectastain kit, Vector laboratories), washed, incubated with the chromogenic substrate (Impact Novared, Vector laboratories) and counterstained with Mayer hematoxylin. Coverslipped slides were imaged by transmitted light microscopy, using an Olympus BX60 microscope with an UPlanFLN 40x/0.75 NA lens.

**Statistics.** Data are shown as means  $\pm$  s.e.m., with the number of mice (*n*). Survival curves were compared using Kaplan–Meier followed by Log-rank analysis (Mantel-Cox) with Bonferroni correction for multiple comparisons. Analysis of variance followed by Tukey's *post hoc* test for multiple comparisons was used to determine significant differences among groups for body weight, BAL cell and CFUs counts, MCC, BAL mucins content, BALF cytokines and immunoglobulin content, histology scores, and morphometric analyses.  $P < 0.05$  was considered statistically significant.

**SUPPLEMENTARY MATERIAL** is linked to the online version of the paper at <http://www.nature.com/mi>

## ACKNOWLEDGMENTS

We thank Troy Rogers for assistance with mucociliary clearance studies; E. Jane Kelly and Danielle L. Waxer for technical assistance with mouse breeding, phenotyping, and morphometric analyses; Dr Michael Chua for assistance with imaging; Carlton W. Anderson of the UNC CGIBD's Advanced Analytics Core for performing the Multiplex assay; and Alexandra C. Infanzon for editorial assistance.

This work was funded by the Cystic Fibrosis Research Development Program grant RDP CFF R026-CR11 to WKO and the CFF RDP BOUCHE15R0 to RCB, the National Institute of Health (NIH) P30-DK065988, P50-HL060280, P50-HL084934, P50-HL107168, P01-HL108808, P01-HL110873 and UH2-HL123645 (to RCB). The UNC CGIBD's Advanced Analytics Core is supported by NIH grant P30 DK34987.

## AUTHOR CONTRIBUTIONS

A.L.-B., W.K.O., and R.C.B. designed the study; K.J.W. and A.S.V. maintained mouse colonies, generated experimental animals, and collected body weight and survival data; A.L.B. and K.J.W. performed phenotyping experiments involving BAL analyses (differential cell counts, microbiology, etc.) and tissue harvest; K.A.B. provided histological specimens; A.L.-B. performed mucin agarose western blots, histopathological, immunohistochemistry/immunofluorescence, and morphometric analyses; B.R.G. performed and analyzed the data for the MCC assay; C.M.E., provided Muc5ac<sup>-/-</sup> and Muc5b<sup>-/-</sup> mice and reviewed the manuscript; A.L.-B. analyzed the rest of the data, and wrote the manuscript. B.R.G., W.K.O., and R.C.B. contributed to interpretation of the data and reviewed the manuscript.

## DISCLOSURE

Drs Boucher, Grubb, and O'Neal are inventors in US Patent US 7,772,458 B2 for the *Scnn1b*-Tg mouse model. All other authors have no conflict of interest to disclose.

© 2017 Society for Mucosal Immunology

## REFERENCES

- Linden, S.K., Sutton, P., Karlsson, N.G., Korolik, V. & McGuckin, M.A. Mucins in the mucosal barrier to infection. *Mucosal Immunol.* **1**, 183–197 (2008).
- Anderson, W.H. *et al.* The relationship of mucus concentration (hydration) to mucus osmotic pressure and transport in chronic bronchitis. *Am. J. Respir. Crit. Care Med.* **192**, 182–190 (2015).
- Henderson, A.G. *et al.* Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. *J. Clin. Invest.* **124**, 3047–3060 (2014).
- Button, B. *et al.* A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. *Science* **337**, 937–941 (2012).
- Garcia, M.A., Yang, N. & Quinton, P.M. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. *J. Clin. Invest.* **119**, 2613–2622 (2009).
- Gustafsson, J.K. *et al.* Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. *J. Exp. Med.* **209**, 1263–1272 (2012).
- Tang, X.X. *et al.* Acidic pH increases airway surface liquid viscosity in cystic fibrosis. *J. Clin. Invest.* **126**, 879–891 (2016).
- Shah, V.S. *et al.* Airway acidification initiates host defense abnormalities in cystic fibrosis mice. *Science* **351**, 503–507 (2016).
- Kesimer, M. *et al.* Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. *Mucosal Immunol.* **6**, 379–392 (2013).
- Kesimer, M., Makhov, A.M., Griffith, J.D., Verdugo, P. & Sheehan, J.K. Unpacking a gel-forming mucin: a view of MUC5B organization after granular release. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **298**, L15–L22 (2010).
- Kiwamoto, T. *et al.* Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis. *J. Allergy Clin. Immunol.* **135**, 1329–1340, e1329 (2015).
- McDole, J.R. *et al.* Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. *Nature* **483**, 345–349 (2012).
- Shan, M. *et al.* Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. *Science* **342**, 447–453 (2013).
- Thornton, D.J. & Sheehan, J.K. From mucins to mucus: toward a more coherent understanding of this essential barrier. *Proc. Am. Thorac. Soc.* **1**, 54–61 (2004).
- Kirkham, S., Sheehan, J.K., Knight, D., Richardson, P.S. & Thornton, D.J. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. *Biochem. J.* **361**, 537–546 (2002).
- Thornton, D.J., Rousseau, K. & McGuckin, M.A. Structure and function of the polymeric mucins in airways mucus. *Annu. Rev. Physiol.* **70**, 459–486 (2008).
- Rose, M.C. & Voynow, J.A. Respiratory tract mucin genes and mucin glycoproteins in health and disease. *Physiol. Rev.* **86**, 245–278 (2006).
- Kirkham, S. *et al.* MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **178**, 1033–1039 (2008).
- Roy, M.G. *et al.* Muc5b is required for airway defence. *Nature* **505**, 412–416 (2014).
- Evans, C.M. *et al.* The polymeric mucin Muc5ac is required for allergic airway hyperreactivity. *Nat. Commun.* **6**, 6281 (2015).
- Mall, M., Grubb, B.R., Harkema, J.R., O'Neal, W.K. & Boucher, R.C. Increased airway epithelial Na<sup>+</sup> absorption produces cystic fibrosis-like lung disease in mice. *Nat. Med.* **10**, 487–493 (2004).
- Livraghi-Butrico, A. *et al.* Genetically determined heterogeneity of lung disease in a mouse model of airway mucus obstruction. *Physiol. Genomics* **44**, 470–484 (2012).
- O'Neal, W.K. *et al.* Assessment of genetic modifiers for phenotypic severity of *Scnn1b*-transgenic mice. *Pediatr. Pulmonol.* **42** (Supplement 30), 266 (abstract #184) (2007).
- Mall, M.A. *et al.* Development of chronic bronchitis and emphysema in beta-epithelial Na<sup>+</sup> channel-overexpressing mice. *Am. J. Respir. Crit. Care Med.* **177**, 730–742 (2008).
- Livraghi, A. *et al.* Airway and lung pathology due to mucosal surface dehydration in {beta}-epithelial Na<sup>+</sup> channel-overexpressing mice: role of TNF- $\alpha$  and IL-4R $\alpha$  signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment. *J. Immunol.* **182**, 4357–4367 (2009).
- Roy, M.G. *et al.* Mucin production during prenatal and postnatal murine lung development. *Am. J. Respir. Cell. Mol. Biol.* **44**, 755–760 (2011).
- Livraghi-Butrico, A. *et al.* Mucus clearance, MyD88-dependent and MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial infection and inflammation. *Mucosal Immunol.* **5**, 397–408 (2012).
- Hasnain, S.Z. *et al.* Muc5ac: a critical component mediating the rejection of enteric nematodes. *J. Exp. Med.* **208**, 893–900 (2011).
- Foo, S.Y. & Phipps, S. Regulation of inducible BALT formation and contribution to immunity and pathology. *Mucosal Immunol.* **3**, 537–544 (2010).
- Phalipon, A. *et al.* Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. *Immunity* **17**, 107–115 (2002).
- Gilley, S.K. *et al.* Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **306**, L162–L169 (2014).
- Livraghi, A. & Randell, S.H. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. *Toxicol. Pathol.* **35**, 116–129 (2007).
- Ostrowski, L.E. *et al.* Conditional deletion of *dnaic1* in a murine model of primary ciliary dyskinesia causes chronic rhinosinusitis. *Am. J. Respir. Cell. Mol. Biol.* **43**, 55–63 (2010).
- Zhu, Y. *et al.* Munc13-2<sup>-/-</sup> baseline secretion defect reveals source of oligomeric mucins in mouse airways. *J. Physiol.* **586**, 1977–1992 (2008).
- Rajavelu, P. *et al.* Airway epithelial SPDEF integrates goblet cell differentiation and pulmonary Th2 inflammation. *J. Clin. Invest.* **125**, 2021–2031 (2015).
- Contreras-Ruiz, L. & Masli, S. Immunomodulatory cross-talk between conjunctival goblet cells and dendritic cells. *PLoS One* **10**, e0120284 (2015).
- Knoop, K.A., McDonald, K.G., McCrate, S., McDole, J.R. & Newberry, R.D. Microbial sensing by goblet cells controls immune surveillance of luminal antigens in the colon. *Mucosal Immunol.* **8**, 198–210 (2015).

38. Kesimer, M. *et al.* Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways?. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **296**, L92–L100 (2009).
39. Radicioni, G. *et al.* The innate immune properties of airway mucosal surfaces are regulated by dynamic interactions between mucins and interacting proteins: the mucin interactome. *Mucosal Immunol.* (e-pub ahead of print 13 April 2016).
40. Corthesy, B. Multi-faceted functions of secretory IgA at mucosal surfaces. *Front. Immunol.* **4**, 185 (2013).
41. Lee, S.H. *et al.* Increased expression of vascular endothelial growth factor and hypoxia inducible factor-1alpha in lung tissue of patients with chronic bronchitis. *Clin. Biochem.* **47**, 552–559 (2014).
42. Ehre, C. *et al.* Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs. *Proc. Natl Acad. Sci. USA* **109**, 16528–16533 (2012).